ADS is now offering Buprenorphine (Subutex) in conjunction with our funding partner, Sandhills Center.
About Buprenorphine (Subutex)
Buprenorphine is a leading medication alternative in the treatment of opioid addiction. It became FDA-approved and available to the public in 2002 as a result of the Drug Addiction Treatment Act (DATA 2000). DATA 2000 allowed qualified physicians to prescribe buprenorphine (the active ingredient in Suboxone and Subutex) to individuals suffering with chronic opioid addiction. This provided a new alternative in medication-assisted treatment. Up until this time, methadone had been the only effective medication used for alleviating opioid withdrawal symptoms.
Buprenorphine is an opioid agonist which binds to the body’s opioid receptor cells and reduces or eliminates opiate withdrawal sickness like nausea, diarrhea, cramping, runny nose, and headache.
ADS presently utilizes methadone in its Greensboro Opioid Treatment Program since methadone is the most affordable option and has a history of years of proven effectiveness. Methadone treatment is also covered by Medicaid and State funding for qualifying individuals. Now, Buprenorphine (Subutex) is being offered as a result of additional funding having been made available by Sandhills Center.